New York, June 3, 2026, 07:10 (EDT)
- PDS Biotechnology said Nasdaq closed out a minimum bid price deficiency because the stock came back into compliance.
- PDSB finished Tuesday at $1.16, gaining 1.75%. The stock moved between $1.12 and $1.23.
- The relief takes away a near-term listing overhang. But questions about financing and how clinical trials play out are still central risks for the stock.
PDS Biotechnology Corporation shares traded higher after the cancer immunotherapy company said Nasdaq signed off on its compliance with the $1 minimum bid-price rule. That wraps up a deficiency issue that’s been on the stock since February. The minimum bid requirement says a listed stock has to stay over a certain price to keep its exchange listing.
Nasdaq’s June 2 notice takes off the immediate delisting risk for PDSB, which had traded under $1 for 30 business days in a row earlier this year, according to a filing. The company still faces the same clinical and cash needs as before, but now without the near-term threat of a delisting process tied to that breach.
The stock finished Tuesday at $1.16, up 1.75%. Roughly 1.08 million shares traded hands, company investor-relations data showed. Shares have moved between $0.51 and $1.92 over the past 52 weeks.
U.S. stocks were set for a regular trading day Wednesday. Nasdaq’s 2026 schedule puts the next June holiday closing on June 19 for Juneteenth. At the dateline, trading hadn’t started yet.
PDSB remains a small-cap biotech, with the latest market value at about $64 million. Shares last traded at $1.16, ticking up 3 cents from their previous finish.
PDS’s drug pipeline is still the main focus, as the listing notice hasn’t changed that. The company is testing immunotherapies designed to spur the immune system against cancer. The lead project targets HPV16-positive head and neck cancer.
PDS Biotech CEO Frank Bedu-Addo said in May the company saw “clinical and regulatory progress” in the first quarter and was preparing to restart enrollment in its amended VERSATILE-003 Phase 3 trial. Phase 3 studies are late-stage trials aimed at supporting regulatory approval when results are positive. For the first quarter, PDS Biotech booked a net loss of $7.3 million and ended March with $21.7 million in cash. Pdsbiotech
PDS is testing its shot in a market dominated by Merck’s Keytruda, or pembrolizumab. The VERSATILE-003 trial looks at PDS0101 plus pembrolizumab versus pembrolizumab alone for first-line treatment of recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma, trial listings show. Merck calls Keytruda an anti-PD-1 therapy, meant to boost the immune system’s ability to find and attack tumor cells.
Cancer-immunotherapy stocks traded mixed in early quotes. Iovance Biotherapeutics was last at $4.10, up 14 cents. Agenus slipped to $3.38, down 9.5 cents. The SPDR S&P Biotech ETF stood at $127.76, off $5.83.
The Nasdaq reprieve doesn’t fix the balance sheet. PDS in May said it would issue a $6 million promissory note with 10% yearly interest and hand out warrants for around 2.16 million shares at $1.1824 each. The warrants let investors buy stock at that price. The company also launched an at-the-market, or ATM, program so it can sell shares directly into the market as needed.
PDS shares face clear risks. A drop near $1, slower trial enrollment, weaker data, or a capital raise on tough terms could erase the boost from the Nasdaq listing. PDS is unprofitable, its drugs aren’t approved, and one favorable letter just extends the clock. The investment picture remains uncertain.
